Study of adverse outcomes in women using testosterone therapy

被引:45
作者
van Staa, T. P. [1 ]
Sprafka, J. M. [2 ]
机构
[1] Gen Practice Res Database Med & Healthcare Prod R, London SW8 5NQ, England
[2] Procter & Gamble Pharmaceut, Cincinnati, OH USA
基金
英国医学研究理事会;
关键词
Testosterone; Safety; SEXUAL DESIRE DISORDER; PLACEBO-CONTROLLED TRIAL; POSTMENOPAUSAL WOMEN; MENOPAUSAL WOMEN; RISK-FACTORS; SAFETY; PHARMACOVIGILANCE; DISEASE; PATCH;
D O I
10.1016/j.maturitas.2008.11.001
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Objectives: There are concerns that exogenous testosterone therapy may be associated with adverse cardiovascular effects, increases in risk of breast or uterus cancer and alterations in insulin sensitivity. Objective of this study was to explore the safety of testosterone therapy in actual clinical practice. Methods: Data from the General Practice Research Database and the Health Improvement Network was used, including computerised medical records of UK general practitioners. The study population included women aged 18+ years prescribed testosterone, administered through implants (72.2%), tablets (18.4%) or injections (7.9%). Each testosterone user was matched by age and practice to three control patients. Cox proportional hazards models were used to compare the rates of several outcomes. Results: The study population included 8412 women, 2103 testosterone users and 6309 controls. There were no statistically significant differences between the cohorts in the rates of cerebrovascular disease, ischemic heart disease, breast cancer, deep venous thrombosis/pulmonary embolism, diabetes mellitus or acute hepatitis. The rate of breast cancer was comparable between testosterone users and control patients. The rate of androgenic events was increased in the testosterone cohort (relative rate of 1.55 [95% CI 1.21-1.97]). Differences in outcomes between the cohorts were generally comparable across subgroups based on age and use of hormone therapy. Conclusions: This study found no major increase in the risk of cardiovascular diseases or breast cancer in women using testosterone (implants, tablets, or injections), while the risk of androgenic events was increased. It would be useful to conduct similar studies at lower doses with transdermal testosterone. (c) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:76 / 80
页数:5
相关论文
共 15 条
[1]   GENERALIZING THE RESULTS OF RANDOMIZED CLINICAL-TRIALS [J].
BAILEY, KR .
CONTROLLED CLINICAL TRIALS, 1994, 15 (01) :15-23
[2]   Safety and adverse effects of androgens: How to counsel patients [J].
Basaria, S ;
Dobs, AS .
MAYO CLINIC PROCEEDINGS, 2004, 79 (04) :S25-S32
[3]   Management of female sexual dysfunction in postmenopausal women by testosterone administration: Safety issues and controversies [J].
Braunstein, Glenn D. .
JOURNAL OF SEXUAL MEDICINE, 2007, 4 (04) :859-866
[4]   Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial [J].
Davis, Susan R. ;
van der Mooren, M. J. ;
van Lunsen, Rik H. W. ;
Lopes, Patrice ;
Ribot, Jean ;
Rees, Margaret ;
Moufarege, Alain ;
Rodenberg, Cynthia ;
Buch, Akshay ;
Purdie, David W. .
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2006, 13 (03) :387-396
[5]   Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy [J].
Dimitrakakis, C ;
Jones, RA ;
Liu, A ;
Bondy, CA .
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2004, 11 (05) :531-535
[6]   A double-blind, randomized, placebo-controlled trial of the effect of testosterone cream on the sexual motivation of menopausal hysterectomized women with hypoactive sexual desire disorder [J].
El-Hage, G. ;
Eden, J. A. ;
Manga, R. Zoa .
CLIMACTERIC, 2007, 10 (04) :335-343
[7]   High-dose testosterone is associated with atherosclerosis in postmenopausal women [J].
Hak, A. Elisabeth ;
Westendorp, Iris C. D. ;
Pols, Huibert A. P. ;
Hofman, Albert ;
Witteman, Jacqueline C. M. .
MATURITAS, 2007, 56 (02) :153-160
[8]   Evaluation of the clinical relevance of benefits associated with transdermal testosterone treatment in postmenopausal women with hypoactive sexual desire disorder [J].
Kingsberg, Sheryl ;
Shifren, Jan ;
Wekselman, Kathryn ;
Rodenberg, Cynthia ;
Koochaki, Patricia ;
DeRogatis, Leonard .
JOURNAL OF SEXUAL MEDICINE, 2007, 4 (04) :1001-1008
[9]  
Matthews KA, 1996, AM J EPIDEMIOL, V143, P971
[10]  
Shifren JL, 2006, MENOPAUSE, V13, P770, DOI 10.1097/01.gme.0000227400.60816.52